Cargando…

Eczematous eruption after guselkumab treatment for psoriasis

Detalles Bibliográficos
Autores principales:	Reyn, Birgit, Gils, Ann, Hillary, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820255/ https://www.ncbi.nlm.nih.gov/pubmed/31687468 http://dx.doi.org/10.1016/j.jdcr.2019.09.005

Ejemplares similares

Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab
por: Megna, Matteo, et al.
Publicado: (2022)

Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis
por: Salna, Michael P., et al.
Publicado: (2017)

Tozinameran: Severe eczematous eruption: case report
Publicado: (2022)

Remedies Worth Trying in Eczematous Eruptions of Dogs
Publicado: (1898)

An Eczematous Eruption on the Arm
por: Sugita, Kazunari, et al.
Publicado: (2021)

Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report
por: Xiao, Yu, et al.
Publicado: (2023)

Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient
por: Kim, Sa Rang, et al.
Publicado: (2019)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
por: Chiang, Cheng-Ying, et al.
Publicado: (2021)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Guselkumab for plaque psoriasis
Publicado: (2019)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Eczematous reactions to psoriasis biologics treated with dupilumab: A case series
por: Koschitzky, Merav, et al.
Publicado: (2021)

Tozinameran: Eczematous erythroderma: case report
Publicado: (2022)

The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
por: Song, Eingun James, et al.
Publicado: (2020)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Rare variants of cutaneous leishmaniasis presenting as eczematous lesions
por: Ayatollahi, Jamshid, et al.
Publicado: (2014)

Non-Eczematous Vesiculobullous Skin Eruption after Stevens-Johnson Syndrome: Developed without Intravenous Immunoglobulin Therapy
por: Kim, Jin A, et al.
Publicado: (2014)

Modified dose of guselkumab for treatment of pyoderma gangrenosum
por: Reese, Ashley M., et al.
Publicado: (2022)

A Case of the Safety and Efficacy of Guselkumab in Psoriasis with Alcoholic Liver Cirrhosis
por: Nam, Hyun Min, et al.
Publicado: (2021)

Resolution of transient, marked eosinophilia, hyperimmunoglobulinemia E, and refractory eczematous dermatitis after the treatment of pancreatic pseudocysts
por: Ito, Toshiki, et al.
Publicado: (2015)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum
por: Baier, Cassandra, et al.
Publicado: (2020)

Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris
por: Nishimura, Mai, et al.
Publicado: (2022)

Tumor Necrosis Factor Inhibitor-Induced Eczematous Eruption: A Report of Two Cases and Review of the Literature
por: Pagan-Leon, Sohemi, et al.
Publicado: (2021)

Keratitis following leech therapy for periocular eczematous dermatitis: a case report
por: Özkaya, Dilek
Publicado: (2023)

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
por: Wechter, Todd, et al.
Publicado: (2018)

Guselkumab‐associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature
por: Burlando, Martina, et al.
Publicado: (2021)

Urticarial and Eczematous Eruptions Following mRNA COVID-19 Vaccination in Patients With and Without Chronic Urticaria and Atopic Dermatitis
por: Shah, Ruchi, et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Successful Treatment of Recalcitrant Palmoplantar Pustulosis with Guselkumab
por: Jung, Jang Hwan, et al.
Publicado: (2023)

Progressing eczematous dermatitis in an infantile hemangioma with minimal or arrested growth treated with tacrolimus ointment
por: Alsaid, Raya Qais, et al.
Publicado: (2020)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab
por: Brunner, P.M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_coktikh5v07245gct72akchvne